Document Detail


Different effects of naloxone on the growth hormone response to melatonin and pyridostigmine in normal men.
MedLine Citation:
PMID:  9667227     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The effect of melatonin (MEL) (12 mg orally), pyridostigmine (60 mg orally), the combination of MEL and pyridostigmine, or placebo on growth hormone (GH) secretion was tested in seven normal men. In addition, MEL tests and pyridostigmine tests were repeated after pretreatment with naloxone (1.2-mg bolus followed by intravenous [i.v.] infusion of 1.6 mg/h for 3 hours). Serum GH levels increased fivefold after MEL and sixfold after pyridostigmine administration. The concomitant administration of MEL did not change the GH response to pyridostigmine. In the presence of naloxone, the GH response to MEL was completely abolished, whereas naloxone did not modify the pyridostigmine-induced GH increase. These data suggest that MEL and pyridostigmine stimulate GH secretion through a common mechanism, which is probably represented by the inhibition of somatostatin activity. However, in contrast to pyridostigmine, the action of MEL appears to be exerted through a naloxone-sensitive opioid mediation.
Authors:
V Coiro; R Volpi; L Capretti; N Giuliani; G Caffarri; R Colla; C Marchesi; P Chiodera
Related Documents :
7868307 - The role of plasma growth hormone, prolactin, triiodothyronine and tetraiodothyronine i...
3571017 - Determination of the temporal relationship between porcine growth hormone, serum igf-1 ...
8690107 - Age-dependent decrease in the growth hormone response to growth hormone-releasing hormo...
170027 - Hypothalamic hormone interaction in acromegaly.
3954457 - Intracellular and extracellular sulphydryl levels in rheumatoid arthritis.
8781637 - Determination of mineral, parathyroid hormone, and 6-keto-prostaglandin-f1 alpha levels...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Metabolism: clinical and experimental     Volume:  47     ISSN:  0026-0495     ISO Abbreviation:  Metab. Clin. Exp.     Publication Date:  1998 Jul 
Date Detail:
Created Date:  1998-07-23     Completed Date:  1998-07-23     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375267     Medline TA:  Metabolism     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  814-6     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Institute of Psychiatry, School of Medicine, University of Parma, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Human Growth Hormone / biosynthesis*,  blood,  drug effects*
Humans
Infusions, Intravenous
Injections, Intravenous
Male
Melatonin / administration & dosage*,  antagonists & inhibitors
Naloxone / administration & dosage*
Pyridostigmine Bromide / administration & dosage*,  adverse effects
Chemical
Reg. No./Substance:
101-26-8/Pyridostigmine Bromide; 12629-01-5/Human Growth Hormone; 465-65-6/Naloxone; 73-31-4/Melatonin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reoxygenation injury affects isolated islet response to fatty acid stimulation.
Next Document:  Effect of immunosuppression on kidney and serum insulin-like growth factor-I (IGF-I), IGF binding pr...